BET inhibitor molibresib for the treatment of advanced solid tumors: Final results from an open-label phase I/II study.

Sophie Cousin,Jean-Yves Blay,Irene Braña Garcia,Johann S. de Bono,Christophe Le Tourneau,Victor Moreno,José Manuel Trigo,Christine L. Hann,Arun Azad,Seock-Ah Im,Geraldine Ferron-Brady,Antara Datta,Yuehui Wu,Thierry Horner,Brandon E. Kremer,Arindam Dhar,Peter J. ODwyer,Geoffrey I. Shapiro,Sarina Anne Piha-Paul

BET inhibitor molibresib for the treatment of advanced solid tumors: Final results from an open-label phase I/II study.

2020

Sophie Cousin
Jean-Yves Blay
Irene Braña Garcia
Johann S. de Bono
Christophe Le Tourneau
Victor Moreno
José Manuel Trigo
Christine L. Hann
Arun Azad
Seock-Ah Im
Geraldine Ferron-Brady
Antara Datta
Yuehui Wu
Thierry Horner
Brandon E. Kremer
Arindam Dhar
Peter J. ODwyer
Geoffrey I. Shapiro
Sarina Anne Piha-Paul

3618Background: Molibresib is an orally available, small molecule bromodomain and extra-terminal domain (BET) protein inhibitor under investigation for treatment of advanced solid tumors. Methods: ...

Keywords:

open label
Cancer research
Medicine
BET inhibitor
Pathology
phase i ii

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations